Hemoglobin crosfumaril

Drug Profile

Hemoglobin crosfumaril

Alternative Names: DCLHb; Diaspirin crosslinked haemoglobin; Haemoglobin crosfumaril; HemAssist; Human haemoglobin - Baxter

Latest Information Update: 10 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Septic shock
  • Discontinued Hypovolaemia; Shock; Stroke; Vascular disorders

Most Recent Events

  • 20 Apr 2000 Preclinical development for Septic shock in Canada (IV-infusion)
  • 29 Jun 1999 Discontinued-Clinical for Stroke in USA (IV)
  • 29 Jun 1999 A study has been added to the adverse events and Neurological disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top